Roche, the majority shareholder in Chugai Pharmaceutical, is focused on advancing treatments for neurological disorders, including Parkinson's disease, which affects over 10 million people globally. The company is investigating various approaches to slow disease progression and improve patient quality of life, while also committing to sustainability and personalized healthcare. Founded in 1896, Roche has become a leader in biotechnology and diagnostics, aiming for net zero emissions by 2045.
Roche is offering $9.00 per share in cash for Poseida Therapeutics, along with a contingent value right worth up to $4.00 per share. The tender offer expires on January 7, 2025, and the acquisition is expected to close in the first quarter of 2025, pending regulatory approvals and majority share tendering. Risks include potential competing offers, regulatory hurdles, and legal proceedings.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
